Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 679-769-5 | CAS number: 2675-94-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 1993-05-18 to 1993-06-07
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 993
- Report date:
- 1993
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- 1987
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- N,N-diethylprop-2-enamide
- EC Number:
- 679-769-5
- Cas Number:
- 2675-94-7
- Molecular formula:
- C7-H13-N-O
- IUPAC Name:
- N,N-diethylprop-2-enamide
Constituent 1
- Specific details on test material used for the study:
- Batch No.: not specified
Purity: not specified
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Ltd., Bicester, Oxon, England
- Age at study initiation: approximately four to seven weeks of age
- Weight at study initiation: 112 to 158g
- Housing: be housed in groups of up to five rats of the same sex in metal cages with wire floors
- Diet: Biosure LAD
- Water: Anglian water
- Acclimation period: a minimun period of seven days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 21
- Humidity (%): 58
- Air changes (per hr): 10 to 15
- Photoperiod (hrs dark / hrs light): 12 hours artificial light in each 24 hours period
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on oral exposure:
- Test substance preparation: the test item was administered at a volume not exceeding 0.87mL/kg in the main study. The absorption of the test itme was not determined.
- Doses:
- 500, 640 and 800 mg/kg bodyweight
- No. of animals per sex per dose:
- five male and five females per dosage
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: clinical signs: day 1, 5 and 14 after dosing. body weight: day 1, 8 and 15 or death
- Necropsy of survivors performed: yes
Results and discussion
- Preliminary study:
- A preliminary stuy was carried out by doing two male and two female rats at 800mg/kg bodyweight.
The results of preliminary study indicated that the acute lethal oral dose to male and female rats on test item was in the region of 800 mg/kg bodyweight.
Effect levelsopen allclose all
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 739 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 619 - < 1 600
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 716 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 528 - < 1 512
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 762 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 500 - < 2 095
- Mortality:
- There were deaths among male and female rats at 500 mg/kg bodyweight and above. Deaths occured from Day 3 until Day 5. Among the decedents one female dosed at 800 mg/kg was sacrificed (Day 3 on humane grounds.
Slight bodyweight loss was record for all rats that died.
Macroscopic exmination of these animals revealed congestion of blood vessels and a free red substance in the cranial cavity in one male and female dosed at 800 mg/kg. - Clinical signs:
- other: Pilo-erection was observed in all rats within four minutes of dosing and throughout the remainder if Day 1. This sign persisted and was accompanied on Day 1 and/or later intervals by: abnormal body carriage (hunched posture), abnormal gait (waddling), le
- Gross pathology:
- No macroscopic abnormalities were observed for animals killed on Day 15.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The acute median lethal oral doses (LD50) and their 95% confidence limits to rats of test item was estimated to be: Males and females combined 739 mg/kg bodyweight, 619 to 1600 mg/kg bodyweight.
- Executive summary:
The study was carried out in compliance with the guidelines OECD No.401 "Acute Oral Toxicity" . Adopted: 24 February 1987.
Group of ten fasted rats (five males and five females) were given in a single dose by gaveage of the test substance, as supplied, at dose level of 500, 640 and 800 mg/kg bodyweight. All animals surviving treatment were killed and examined macroscopically on Day 15, the end of observation period.
There were deaths among male and female rats at 500 mg/kg bodyweight and above. Deaths occurred from Day 3 until Day 5. Among the decedents one female dosed at 800 mg/kg was sacrificed (Day 3 on humane grounds. Slightly bodyweight loss were recorded for all decedents. Macroscopic examination of these animals revealed congestion of blood vessels and free red substance in the cranial cavity in one male and one female dosed at 800 mg/kg.
Principal clinical signs of reaction to treatment were pilo-erection, abnormal body carriage (hunched posture), abnormal gait (waddling), lethargy, decrease respiration rate, partially clised eyes, pallor of extremities, increased salivation, body tremors and cold body surface. Less commonly observed were clonic convulsions (characterized by repetitive symmetrical jerks or twitching of limbs), increased lacrimation, increase locomotor activity (when disturbed), hypersensitivity, arching of back, followed by falling over and pink extremities. Recovery of surviving rats, as judged by external appearance and behavior, was completed by either Day 6 0r 7 for rats at 500 mg/kg, Day 5 or 9 for rats at 640 mg/kg, or rats at 800 mg/kg, by Day 5 or 7.
Among surviving rats, slightly low bodyweight gains were recorded on Day 8 for two males and two females treated at 500 mg/kg, four female dosed at 640 mg/kg and one male and two females treated at 800 mg/kg; with the exception of one male treated at 800 mg/kg (which also showed a slightly low bodyweight gain on Day 15), these rats achieved anticipated gains on Day 15. All other rats achieved anticipated bodyweight gains throughout the study.
No macroscopic abnormalities were observed for animals killed on Day 15.
The acute median lethal oral doses (LD50) and their 95% confidence limits to rats of test item was estimated to be:
Males and females combined: LD50: 739 mg/kg bodyweight, 95% confidence limits: 619 to 1600 mg/kg bodyweight
Male only: LD50: 716 mg/kg bodyweight, 95% confidence limits: 528 to 1512 mg/kg bodyweight
Female only: LD50: 762 mg/kg bodyweight, 95% confidence limits: 500 to 2095 mg/kg bodyweight
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.